Hexarelin
Research Goal: Analyzing peak GH pulse amplitude and the protective effects of Hexarelin on cardiac myocytes via CD36 receptors.
Route
Subcutaneous injection
Dose range
100 mcg – 200 mcg
Frequency
Once daily (due to desensitization risk)
Cycle length
4 weeks on, followed by a 4-week washout to maintain pituitary sensitivity
Overview
Research Goal: Analyzing peak GH pulse amplitude and the protective effects of Hexarelin on cardiac myocytes via CD36 receptors.
Preparation: Reconstitute with 2.0 mL bacteriostatic water (Conc: 1 mg/mL or 2.5 mg/mL).
Studied benefits
- One of the strongest GHRPs available, known for providing a massive spike in Growth Hormone
- It also offers unique heart-protective (cardioprotective) properties and is used for intense recovery and strength building
Reported side effects
- Carries the highest risk of receptor desensitization (tachyphylaxis) among GHRPs, necessitating regular cycling
- It may also cause temporary increases in cortisol and prolactin
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Phase | Daily Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Standard | 100 mcg | 4 units (0.04 mL) | + Log |
| Advanced | 200 mcg | 8 units (0.08 mL) | + Log |
Frequency
Once daily (due to desensitization risk).
Timing
Evening or immediately post-training.
Cycle length
4 weeks on, followed by a 4-week washout to maintain pituitary sensitivity.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
50 doses of 100 mcg per vial
At the starting dose (100 mcg × 7/week for a 4-week cycle) you would use about 2.8 mg, i.e. 1 × 5 mg vial. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, nutrient-dense diet to support the profound GH release and potential cardioprotective effects associated with this potent growth hormone secretagogue. Incorporate resistance training to maximize the improvements in strength and recovery, but monitor cardiovascular markers periodically as part of a comprehensive research protocol. Ensure 7–9 hours of quality sleep to facilitate cellular repair and synchronize with natural hormonal rhythms. Because Hexarelin can cause rapid receptor desensitization, implement a "pulsing" schedule (such as 2 weeks on, 1 week off) to maintain sensitivity and consistent performance.
Evidence
Research summaries
Growth hormone secretagogues: history, mechanism of action, and clinical development
Findings: Strong GH pulses, works orally sometimes, potential for heart and muscle wasting fixes.
Hexarelin, a GHRP family star, blasts GH harder than GHRP-6 via ghrelin mimic paths. Human trials show big spikes IV/subQ, milder oral. Unlike natural GHRH, no quick fade. Early tests for GH deficiency, cachexia (muscle loss), heart failure – improved strength, ejection fraction. Sides minimal: hunger, water retention. Evolved to pills like ibutamoren. Sets stage for age-related GH drop therapies. Turbo GH without daily shots.
Read the study ↗Growth hormone-releasing peptides and their analogs
Findings: Potent GH in animals/humans, non-GHRH path for steady boosts, leads to oral drugs.
Hexarelin outpowers earlier GHRPs in rats, beagles, humans – GH jumps 10-20x baseline. Acts on unique receptors, synergizes with GHRH. Pushed field to small-molecule mimics for easy dosing. Used in obesity, frailty studies for fat loss/muscle gain. Reliable across species, hinting human longevity perks.
Read the study ↗Agonists of growth hormone-releasing hormone (GHRH) receptor inhibit experimental lung cancer... (notes hexarelin parallels)
Findings: GH pathway for anti-cancer synergy, organ protection like heart/lungs.
While GHRH-focused, hexarelin-like secretagogues shrink tumors, aid radiation. Heart post-MI recovery, diabetes eye fixes in animals. Hexarelin's potency amps these. Broad repair: wounds, arteries. Emerging for non-growth uses.
Read the study ↗Effect of GHRH and GHRP-2 treatment... (extends to hexarelin family)
Findings: Synergy for max GH, cell morphology tweaks for sustained release.
GHRP family incl. hexarelin analogs up GH receivers, Pit-1 genes in sheep cells. With GHRH, explosive output. Changes cell shape for better signaling. Foundation for blends in therapy.
Read the study ↗More references (5)
- Growth Hormone Secretagogues and their Cardiovascular Effects, 2021
- Hexarelin: A Powerful Stimulus of GH Secretion in Pubertal Children and Adults, 2016 (Re-evaluation)
- Cardioprotective effects of Hexarelin in myocardial ischemia models, 2014
- Hexarelin and its interaction with the Pituitary-Adrenal Axis, 2005
- Hexarelin shows no interaction with CRH on ACTH secretion in humans, 1998
Identification
Chemistry
- cas
- 140703-51-1 (primary)
- formula
- C₄₇H₅₈N₁₂O₆ (free peptide); may vary with salt forms
- molecular weight
- 887.0-887.04 g/mol (free peptide); varies with salt forms
- sequence
- H-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ (single-letter code: HMAWFK with D-stereocenters and 2-methyl substitution)
- source
- Synthetic; rationally designed derivative of GHRP-6
- biosynthesis
- Non-ribosomal; chemically synthesized through peptide bond formation
- type
- Linear peptide; C-terminal amidation; contains D-amino acids and 2-methyl-modified tryptophan
Keep exploring
Related peptides
ARA-290
ARA290 · Cibinetide
- Route
- Subcutaneous
- Dose
- 4 mg – 8 mg
- Cycle
- 4–8 weeks
B7-33
B7-33 peptide · RXFP1 agonist B7-33
- Route
- Subcutaneous
- Dose
- 150 mcg – 500 mcg
- Cycle
- 4–8 weeks for acute fibrosis studies
Bronchogen
AEDL · Ala-Glu-Asp-Leu peptide
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 10–20 days; often repeated every 4–6 months
Cardiogen
AEDR · Ala-Glu-Asp-Arg peptide
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 10–20 days